These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28579000)

  • 1. Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R. S. Lance, P. S. Nelson, I. M. Thompson, Jr., A. A. Wagner, J. T. Wei and D. W. Lin J Urol 2017;197:1026-1033.
    Denize J; Nouhaud FX; Cornu JN; Pfister C
    J Urol; 2017 Sep; 198(3):709-711. PubMed ID: 28579000
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from Canary Prostate Cancer Active Surveillance StudyJ. M. Schenk, L. F. Newcomb, Y. Zheng, A. V. Faino, K. Zhu, Y. A. Nyame, J. D. Brooks, P. R. Carroll, M. R. Cooperberg, A. Dash, C. P. Filson, M. E. Gleave, M. Liss, F. M. Martin, T. M. Morgan, P. S. Nelson, I. M. Thompson, A. A. Wagner and D. W. Lin
    Powell IJ; Heilbrun LK; Kittles RA
    J Urol; 2021 Feb; 205(2):338-339. PubMed ID: 33155865
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study.
    Olumi AF
    Urol Oncol; 2014 Feb; 32(2):211. PubMed ID: 24445293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer: S. Loeb, M. G. Sanda, D. L. Broyles, S. S. Shin, C. H. Bangma, J. T. Wei, A. W. Partin, G. G. Klee, K. M. Slawin, L. S. Marks, R. H. N. van Schaik, D. W. Chan, L. J. Sokoll, A. B. Cruz, I. A. Mizrahi and W. J. Catalona J Urol 2015;193:1163-1169.
    Shah N; Ioffe V
    J Urol; 2015 Dec; 194(6):1825-6. PubMed ID: 26354886
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12.
    Yuan R
    Eur Urol; 2018 Dec; 74(6):e149-e150. PubMed ID: 30177284
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12.
    Kearns JT; Newcomb LF; Lin DW
    Eur Urol; 2018 Dec; 74(6):e151. PubMed ID: 30195835
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance-How Many Cores are Enough?: K. N. Pham, C. R. Porter, K. Odem-Davis, E. M. Wolff, C. Jeldres, J. T. Wei and T. M. Morgan J Urol 2015;194:674-679.
    Zhou Z; Yan W; Ji Z
    J Urol; 2016 May; 195(5):1624-1625. PubMed ID: 26876586
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006.
    Walsh PC
    J Urol; 2006 Dec; 176(6 Pt 1):2744; author reply 2744. PubMed ID: 17085206
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110.
    Catalona WJ
    J Urol; 2011 Nov; 186(5):2131-2; author reply 2132. PubMed ID: 21945513
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Factors predicting prostatic biopsy Gleason sum under grading: D. A. Stackhouse, L. Sun, F. R. Schroeck, J. Jayachandran, A. A. Caire, C. O. Acholo, C. N. Robertson, D. M. Albala, T. J. Polascik, C. F. Donatucci, K. E. Maloney and J. W. Moul J Urol 2009; 182: 118-124.
    Labanaris AP; Kühn R; Zugor V
    J Urol; 2010 Jan; 183(1):396-7; author reply 397-8. PubMed ID: 19945124
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Small prostate size and high grade disease--biology or artifact?: J. J. Liu, J. D. Brooks, M. Ferrari, R. Nolley and J. C. Presti, Jr. J Urol 2011; 185: 2108-2111.
    Calışkan S
    J Urol; 2011 Dec; 186(6):2504; author reply 2504-5. PubMed ID: 22019038
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J. B. Malcolm, M. D. Fabrizio, B. B. Barone, R. W. Given, R. S. Lance, D. F. Lynch, J. W. Davis, M. E. Shaves and P. F. Schellhammer. J Urol 2010; 183: 1822-1828.
    Parker AS
    J Urol; 2011 May; 185(5):1983-4. PubMed ID: 21439591
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Update on AUA guideline on the management of benign prostatic hyperplasia: K. T. McVary, C. G. Roehrborn, A. L. Avins, M. J. Barry, R. C. Bruskewitz, R. F. Donnell, H. E. Foster, Jr., C. M. Gonzalez, S. A. Kaplan, D. F. Penson, J. C. Ulchaker and J. T. Wei J Urol 2011; 185: 1793-1803.
    Abrams P
    J Urol; 2012 Jan; 187(1):358-9; author reply 359. PubMed ID: 22119362
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. Terris, K. Walker, C. L. Amling, P. R. Carroll and M. R. Cooperberg J Urol 2016;196:1408-1414.
    Heilbrun LK; Powell IJ
    J Urol; 2018 Jan; 199(1):305-306. PubMed ID: 28961419
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study: J. E. Thompson, D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, M. Pulbrook, M. Böhm, A.-M. Haynes, A. Hayen and P. D. Stricker J Urol 2014;192:67-74.
    El-Shater Bosaily A; Arya M; Punwani S; Emberton M; Kirkham A; Freeman A; Ahmed HU
    J Urol; 2015 Feb; 193(2):735-6; discussion 736. PubMed ID: 25445580
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate BiopsiesA. Amin, M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. van Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson
    Montorsi F; Gandaglia G; Fossati N; Briganti A
    J Urol; 2020 Oct; 204(4):843. PubMed ID: 32609573
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. S. T. dos Reis, J. Pontes, Jr., F. E. Villanova, P. M. D. Borra, A. A. Antunes, M. F. Dall'oglio, M. Srougi and K. R. M. Leite. J Urol 2009; 181: 2320-2325.
    Ahirwar DK; Mittal RD
    J Urol; 2010 Mar; 183(3):1258. PubMed ID: 20097381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.